News Johnson & Johnson Deutsche Boerse AG

Equities

JNJ0

CA47817E1034

Delayed Deutsche Boerse AG Other stock markets 02:16:26 2024-05-28 EDT			5-day change	1st Jan Change
12.9 ^EUR	0.00%		-3.01%	-5.84%

06:45pm	Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	MT
05:56pm	Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	12:45pm	MT
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	11:56am	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	09:59am	MT
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	09:15am	MT
Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	09:14am	MT
J&J: acquisition of Swiss eczema biotech company	08:34am	CF
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal	08:10am	DJ
J&J acquires rights to skin disorder drug for $1.25 bln	07:37am	RE
Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	07:35am	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	07:32am	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	05-24	AQ
J&J: to present advances at ASCO and EHA	05-24	CF
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	05-24	PU
Some of the biggest splits in Corporate America	05-23	RE
Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	05-22	RE
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	05-22	MT
Top Midday Stories: US Targets August 1 Start Date for China Tariff Hikes; CFPB Says BNPL Requires Credit Card-Level Oversight; Target Shares Fall on Earnings Miss; Third BHP Bid Rejected by Anglo American	05-22	MT
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	05-22	BU
Johnson & Johnson Allegedly Engaged in 'Bad Faith' Bankruptcies That Harm Talc Victims, Lawsuit Says	05-22	MT
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	05-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm